Tools for Practice Outils pour la pratique

#318 Tranexamic Acid – Golden in the golden hours of trauma?

Does Tranexamic acid (TXA) in general adult trauma or traumatic head injuries improve mortality or disability without increased risk of adverse events?

Giving TXA to adult trauma patients within 3 hours of injury reduces overall mortality from 16% with placebo to 14.5% at 28 days. Giving TXA to isolated head injury patients within 3 hours decreases head injury death in patients with Glasgow Coma Scale (GCS) >3 (from 14% with placebo to 12.5%), largely driven by improvements in patients with GCS 9-15. Serious adverse events were similar to placebo.

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

  • Two large randomized, placebo-controlled trials of intravenous TXA (1g over 10 minutes, then 1 g over 8 hours) in adult trauma. Patients >80% male, median age 35-42 years. Outcomes at 28 days.
  • General trauma: 20,211 patients with signs of shock or risk of significant hemorrhage, presenting within 8 hours of injury. 31% had co-existing head injury.1,2
    • All-cause mortality: 14.5% versus 16% placebo; number needed to treat (NNT)=67.
      • Only treatment ≤3 hours improved mortality (treatment >3 hours: No difference).
    • Adverse events: Vascular occlusive event (myocardial infarction, stroke, pulmonary embolism) 1.7% versus 2.0% placebo, not statistically different.
  • Traumatic brain injury: 12,737 patients with GCS of ≤12 or intracranial bleeding on CT and no major extracranial bleeding.3,4 Allowable time post-injury changed from 8 to ≤3 hours during study. Outcomes [for patients presenting ≤3 hours (N=9202)]:
    • All-cause mortality: No difference.
    • Head injury mortality (overall): No difference.
      • Analyzed by severity of head injury (some pre-specified):
        • Excluding GCS=3: 12.5% versus 14% placebo NNT=67.
        • GCS 4-8 no difference.
        • GCS 9-15: 5.8% versus 7.5% placebo NNT=59.
      • Disability scores similar between groups.
      • Adverse events: No difference.
      • Limitation: No statistical correction for multiple sub-group analyses.
    • Systematic reviews5,6 dominated by above studies found similar outcomes.

  • Hemorrhage causes 20-45% of trauma deaths.7,8,9
  • Guidelines recommend using TXA within 3 hours in :
    • "Severely injured bleeding patients."10
    • "Patients with major trauma and active or suspected bleeding."11
  • Pre-hospital TXA did not improve:
    • Mortality in general trauma.12
    • Neurological outcomes in traumatic brain injury patients.13

Jake Donaldson July 16, 2022


Gilbert Bretecher November 6, 2022

minimal benefit with TXA

Jesse Fontaine July 26, 2023

Almost a 10% relative increase in survival. It’s worth it.

Latest Tools for Practice
Derniers outils pour la pratique

#369 Remind me, do medications that target brain amyloid improve my dementia?

Are amyloid-targeting monoclonal antibodies safe and effective for mild cognitive impairment or Alzheimer’s dementia?
Read Lire 0.25 credits available Crédits disponibles

#368 Sodium Restriction in Heart Failure: Beneficial or pouring salt in the wound?

Does sodium restriction improve outcomes in patients with chronic heart failure?
Read Lire 0.25 credits available Crédits disponibles

#367 Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

What are the risks and benefits of ubrogepant for the acute treatment of episodic migraines?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session

  • Jennifer Young MD CCFP-EM
  • Elfriede Cross MD FRCPC
  • Michael R Kolber MD CCFP MSc

1. CRASH-2 trial Collaborators. Lancet. 2010; 376: 23-32.

2. Roberts I, Shakur H, Coats T, et al. Health Technol Assess. 2013; 17 (10): ISSN 1366-5278.

3. CRASH-3 trial Collaborators. Lancet. 2019; 394:1713–23.

4. Roberts I, Shakur-still H, Aeron-Thomas A, et al. Health Technology Assess. 2021: 25(26): ISSN 1366-5278.

5. Ker K, Roberts I, Coats T. Cochrane Database Syst Rev. 2015; (5):CD004896.

6. Lawati K, Sharif S, Al Maqbali A, et al. Intensive Care Med. 2021; 47(1): 14-27.

7. Ackery A, Rizoli S. CMAJ. 2014; 186:15.

8. Wong J, George R, Hanley C, et al. Can J Anesth. 2021 ;68:894-917.

9. Callcut R, Kornblith L, Conroy A, et al. J Trauma Acute Care Surg 2019; 86(5):864–870.

10. Cannon, JW, Khan, MA, Raja, AS, et al. J Trauma Acute Care Surg 2017; 82(3):605-617.

11. National Institute for Health and Care Excellence (NICE) 2016 (Guideline, No. 39) Assessment and management of hemorrhage. Available from: Accessed April 2, 2022.

12. Guyette F, Brown B, Zenati M, et al. JAMA Surgery. 2020; 156(1): 11-20.

13. Rowell S, Meier E, McKnight B, et al. JAMA. 2020; 324(10):961-974.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.